- Home
- LION vs IBRX Comparison
LION vs IBRX Comparison
Compare LION & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LION
- IBRX
- Stock Information
- Founded
- LION 1997
- IBRX 2014
- Country
- LION United States
- IBRX United States
- Employees
- LION N/A
- IBRX N/A
- Industry
- LION Movies/Entertainment
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LION Consumer Discretionary
- IBRX Health Care
- Exchange
- LION Nasdaq
- IBRX Nasdaq
- Market Cap
- LION 2.1B
- IBRX 2.4B
- IPO Year
- LION N/A
- IBRX N/A
- Fundamental
- Price
- LION $7.43
- IBRX $3.14
- Analyst Decision
- LION Strong Buy
- IBRX Strong Buy
- Analyst Count
- LION 3
- IBRX 5
- Target Price
- LION $11.50
- IBRX $11.35
- AVG Volume (30 Days)
- LION 219.9K
- IBRX 5.8M
- Earning Date
- LION 05-22-2025
- IBRX 03-03-2025
- Dividend Yield
- LION N/A
- IBRX N/A
- EPS Growth
- LION N/A
- IBRX N/A
- EPS
- LION N/A
- IBRX N/A
- Revenue
- LION $3,005,900,000.00
- IBRX $14,745,000.00
- Revenue This Year
- LION $6.05
- IBRX $753.44
- Revenue Next Year
- LION $6.66
- IBRX $174.29
- P/E Ratio
- LION N/A
- IBRX N/A
- Revenue Growth
- LION 2.59
- IBRX 2270.58
- 52 Week Low
- LION $6.13
- IBRX $2.28
- 52 Week High
- LION $12.84
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- LION 39.52
- IBRX 54.11
- Support Level
- LION $7.41
- IBRX $2.69
- Resistance Level
- LION $7.76
- IBRX $2.89
- Average True Range (ATR)
- LION 0.33
- IBRX 0.21
- MACD
- LION -0.06
- IBRX 0.05
- Stochastic Oscillator
- LION 14.02
- IBRX 58.23
About LION Lionsgate Studios Corp. Common Shares
Lionsgate Studios Corp is a company encompasses world-class motion picture and television studio operations and the STARZ-branded premium global subscription platforms to bring a unique and varied portfolio of entertainment to consumers around the world. The Studio Business consists of the Motion Picture and Television Production reportable segments, together with substantially all of Lionsgate's corporate general and administrative costs. Motion Picture consists of the development and production of feature films, acquisition of North American and worldwide distribution rights. Television Production consists of the development, production and worldwide distribution of television productions including television series, television movies and mini-series, and non-fiction programming.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.